TDR Examines Pharmaceutical-Grade Cannabis and Botanical Drug Exclusivity

The Dales Report reviewed how proposed 12-year exclusivity for FDA-approved botanical drugs could improve investment economics for complex cannabis medicines and why validated GMP processes matter more than extraction capacity alone. Oklahoma processors should view the discussion as an early signal that pharmaceutical opportunities will require documented process control, reproducibility and federal-grade compliance.